Form 4 for BVS Bioventus Inc.
Accepted 2025-03-21 00:00:00 ET · period of report 2025-03-21 · accession 0001578563-25-000187 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-21 | 2025-03-21 | BVS | Singleton Mark Leonard | SVP, CFO | M - OptEx | $0.00 | +18.6K | 137.4K | +16% | $0 |
| D | 2025-03-21 | 2025-03-21 | BVS | Singleton Mark Leonard | SVP, CFO | M - OptEx | $0.00 | -18.6K | 18.6K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-03-21 | M | A | 18,625 | $0.00 | 137,442 | D | — | — | |
| 2 | Derivative | Restricted Stock Units | 2025-03-21 | M | D | 18,625 | $0.00 | 18,625 | D | — · — to — | 18,625 Class A Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. (F2) The original grant of 74,500 RSUs vests in four approximately equal annual installments that began on March 21, 2023. |